Filing summary
Entity discrepancy: The request identifies Elutia Inc., but the supplied Form 10-Q is for Aziyo Biologics, Inc. (Nasdaq: AZYO). This summary covers Aziyo’s quarter ended June 30, 2021, filed August 10, 2021.
Business context and reporting period
Aziyo is a commercial-stage regenerative medicine company selling tissue-based products for implantable medical devices, cardiovascular procedures, orthopedic/spinal repair and soft-tissue reconstruction. It also processes tissue under contract manufacturing arrangements. The filing reports the second quarter and first six months of 2021, compared with the same 2020 periods.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Net sales | $12.2m | $8.6m | $25.0m | $18.4m |
| Gross profit | $5.6m | $3.8m | $11.9m | $9.0m |
| GAAP gross margin | 46.2% | 44.1% | 47.7% | 48.8% |
| Operating loss | $(4.6)m | $(3.8)m | $(8.3)m | $(6.9)m |
| Net loss | $(2.4)m | $(5.2)m | $(7.5)m | $(9.7)m |
Q2 sales rose 41.7%; first-half sales rose 35.8%. Core Products generated $10.0m of Q2 sales and $20.6m for the first half. Non-Core Products generated $2.2m and $4.4m, respectively. First-half gross margin fell year over year; management attributed the decline in adjusted gross margin to the FiberCel recall, product returns, inventory write-downs related to donor-clearance changes, and product mix. The filing’s non-GAAP gross margin excluding acquired-intangible amortization was 53.1% for Q2 and 54.5% for the first half.
Q2 and first-half net losses were reduced by $3.6m of other income: forgiveness of the approximately $3.0m PPP loan and a $550,000 payment from KeraLink under a prior settlement. These are unusual items, not recurring operating sales.
Cash and restricted cash were $28.4m at June 30, 2021, down from $39.5m at year-end 2020. For the first half, operating cash use was $6.0m, investing cash use was $0.2m, and financing cash use was $5.0m; cash declined $11.2m. Current assets were $48.2m and current liabilities $23.6m. The company reported $19.8m of term-loan debt, $2.9m drawn on its revolving facility, and a $1.4m supplier note; it also had a $16.6m long-term revenue-interest obligation and $2.8m current portion. Revolver availability was $5.1m. The debt facilities are secured by company assets and include a monthly minimum-revenue covenant; Aziyo reported compliance at June 30.
Material changes and management commentary
- Growth reflected higher demand and a reduced COVID-19 impact compared with 2020, as well as revenue from new Non-Core contracts signed in late 2020. Management cautioned that seasonality historically results in higher fourth-quarter sales.
- Following the June 2, 2021 voluntary recall of one FiberCel donor lot, Medtronic suspended purchases of FiberCel and other supplied Non-Core products. Management estimated the suspension reduced first-half Core Product sales by about $1.1m and said Core Product sales in coming quarters would likely decline from then-current levels.
- Operating expenses increased: first-half sales and marketing rose 11.2%, general and administrative rose 52.3%, and research and development rose 32.5%. G&A growth primarily reflected public-company costs, including insurance, legal fees and stock compensation. R&D investment included CanGaroo development; manufacturing validation was completed during the quarter.
Outlook, risks and contingencies
Management expected IPO proceeds, cash, revolver availability and anticipated commercial sales to fund operating and capital needs through the third quarter of 2022, while warning that assumptions could prove wrong and funds could be exhausted sooner. Aziyo expected continuing losses and could not predict when, or whether, it would become profitable; additional financing may be needed.
The filing describes 27 FiberCel-related lawsuits alleging tuberculosis infections and other harm after implantation, including claims for damages and medical monitoring. The company said it could not estimate a possible loss range and that an adverse outcome could materially affect its financial position and results. It expects some defense costs or settlements may be insured, but coverage is contested or not guaranteed and may be insufficient. The recalled lot comprised 154 units from one donor shipped to facilities in 20 states; the filing states that eight cases had resulted in fatalities. The FDA inspected the Richmond facility without issuing Form 483 observations.
Other material risks include continued COVID-19 disruption to procedures and sales; dependence on commercial partners and sales agents; product safety, regulatory and recall exposure; debt and the Ligand revenue-interest obligation; covenant compliance; and the possibility of future capital needs. The filing reports no off-balance-sheet arrangements and states that disclosure controls were effective as of June 30, 2021.
Important facts for investors to verify
- Confirm that Aziyo Biologics—not Elutia Inc.—is the issuer intended by the request.
- Track Medtronic’s suspension, any resumption of purchases, and the resulting effect on sales and margins.
- Monitor FiberCel litigation, insurance coverage, recall-related costs, and any new regulatory findings; the filing provides no estimable loss range.
- Assess cash burn and financing needs against management’s stated runway through Q3 2022, including the impact of debt service and revenue-interest payments.
- Check whether sales growth translates into improving underlying margins and reduced operating losses, excluding the PPP forgiveness and KeraLink settlement income.